Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simmiparib in Advanced Malignant Tumors
NCT02993913Phase 1Unknown
- Sponsor
- Acebright
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simmiparib in solid tumor (advanced stage), sponsored by Acebright. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Maximum Plasma Concentration at Day 28 and 2 more. Status: unknown.
02
Drugs
simmiparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02993913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993913.